C-IJKGDeciduous Therapeutics
senescent cell clearance, immune surveillance activation
clearingimmunotherapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IJKG
C-IJKGC-IJKGsenescent cell clearance, immune surveillance activation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Deciduous Therapeutics senescent cell clearance, immune surveillance activation
Deciduous Therapeutics aims to improve human health span by developing medicines that activate endogenous immune mechanisms responsible for eliminating senescent cells. The company describes senescent cells as a driver of age-related diseases through inflammation and extracellular matrix remodeling. Its approach is based on novel molecules that activate immune surveillance to selectively remove senescent cells.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Deciduous Therapeutics — Early mechanism · Lower middle. Derived deterministically from 8 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical).…
Source: Deterministic